No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GPCR240719P70000
- 35.70
- 0.000.00%
15min DelayClose Jun 28 16:00 ET
0.00High0.00Low
35.70Open35.70Pre Close0 Volume0 Open Interest70.00Strike Price0.00Turnover171.50%IV12.66%PremiumJul 19, 2024Expiry Date30.73Intrinsic Value100Multiplier19DDays to Expiry4.97Extrinsic Value100Contract SizeAmericanOptions Type-0.8986Delta0.0121Gamma1.26Leverage Ratio-0.0631Theta-0.0232Rho-1.13Eff Leverage0.0160Vega
Intraday
- 5D
- Daily
News
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.
Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.
Goldman Sachs and Cantor Fitzgerald have a tacit agreement that the monopoly of "Norris" in the weight loss drug market is difficult to change.
Two top Wall Street analysts have reached a consensus, emphasizing that global weight loss drug market leaders "Novo" may continue to dominate the highly profitable weight loss drug market.
Lilly, Novo Nordisk to Dominate Weight Loss Therapy Market: SA Investing Summit
Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com
Comments
It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics(GPCR.US$
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
1
offering afterhours dobt get trapped
Read more